{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T15:45:10Z","timestamp":1784562310909,"version":"3.55.0"},"reference-count":55,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:00:00Z","timestamp":1740182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bristol Myers Squibb","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]},{"name":"National Cancer Institute\/National Institutes of Health","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Head-to-head evidence comparing repotrectinib against other approved ROS1 tyrosine kinase inhibitors (TKIs) is not currently available. The objective of this study was to indirectly compare progression-free survival (PFS), the objective response rate (ORR), and the duration of response (DoR) for repotrectinib vs. crizotinib and vs. entrectinib in patients with TKI-na\u00efve ROS1+ locally advanced or metastatic non-small-cell lung cancer (aNSCLC). Methods: Using evidence from a systematic literature review, unanchored matching-adjusted indirect comparisons (MAICs) were used to estimate population-adjusted hazard ratios (HRs) for PFS and DoR and odds ratios (ORs) for ORR for repotrectinib vs. crizotinib and vs. entrectinib among patients with TKI-na\u00efve aNSCLC. The MAICs were adjusted for imbalances in baseline patient characteristics that were pre-specified as being prognostic or predictive of treatment effects. Weighted Cox (for PFS and DoR) and logistic (for ORR) regression models were fit. Supplementary analyses (SAs) explored the impact of missing data and modeling assumptions on effect estimates. Results: The evidence base was formed by TRIDENT-1 EXP-1 (repotrectinib; N = 71), a pooled set of five trials involving crizotinib (N = 273), and the pooled ALKA-372\u2013001\/STARTRK-1 and -2 trials (entrectinib; N = 168). After population adjustment, repotrectinib was associated with statistically significant improvements in PFS relative to crizotinib (HR = 0.44; 95% confidence interval [CI]: 0.29, 0.67) and entrectinib (HR = 0.57; 95% CI: 0.36, 0.91). Differences in ORR and DoR were not statistically significant but numerically favored repotrectinib. SAs were consistent with the main analyses across all comparisons. Conclusions: The analysis demonstrated the strong benefits of repotrectinib in PFS, which was robust across different SAs and supported by numerically favorable results for DoR (where available) and ORR. These results, alongside the published TRIDENT-1 clinical data, further support repotrectinib as a potential new standard of care for TKI-na\u00efve patients with ROS1+ aNSCLC.<\/jats:p>","DOI":"10.3390\/cancers17050748","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T07:45:08Z","timestamp":1740469508000},"page":"748","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Population-Adjusted Indirect Treatment Comparisons of Repotrectinib Among Patients with ROS1+ NSCLC"],"prefix":"10.3390","volume":"17","author":[{"given":"J\u00fcrgen","family":"Wolf","sequence":"first","affiliation":[{"name":"Center for Integrated Oncology, University Hospital of Cologne, 50937 Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8522-9354","authenticated-orcid":false,"given":"Sarah","family":"Goring","sequence":"additional","affiliation":[{"name":"Broadstreet HEOR, Vancouver, BC V5Y 1L8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8834-1296","authenticated-orcid":false,"given":"Adam","family":"Lee","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Uxbridge UB8 1DH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byoung Chul","family":"Cho","sequence":"additional","affiliation":[{"name":"Yonsei Cancer Center, Yonsei University College of Medicine, Seoul 03722, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Drilon","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Yuan","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Lawrenceville, NJ 08648, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Ayers","sequence":"additional","affiliation":[{"name":"Broadstreet HEOR, Vancouver, BC V5Y 1L8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5378-0544","authenticated-orcid":false,"given":"Greta","family":"Lozano-Ortega","sequence":"additional","affiliation":[{"name":"Broadstreet HEOR, Vancouver, BC V5Y 1L8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen E.","family":"Korol","sequence":"additional","affiliation":[{"name":"Broadstreet HEOR, Vancouver, BC V5Y 1L8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah G.","family":"Korpach","sequence":"additional","affiliation":[{"name":"Broadstreet HEOR, Vancouver, BC V5Y 1L8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Crabtree","sequence":"additional","affiliation":[{"name":"Broadstreet HEOR, Vancouver, BC V5Y 1L8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7835-0372","authenticated-orcid":false,"given":"Lavanya","family":"Huria","sequence":"additional","affiliation":[{"name":"Broadstreet HEOR, Vancouver, BC V5Y 1L8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe Y.","family":"Calvet","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Lawrenceville, NJ 08648, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Ross","family":"Camidge","sequence":"additional","affiliation":[{"name":"University of Colorado Cancer Center, Aurora, CO 80045, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"K\u00f6nig, D., Savic Prince, S., and Rothschild, S.I. (2021). Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations. Cancers, 13.","DOI":"10.3390\/cancers13040804"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jtho.2018.05.026","article-title":"Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice","volume":"13","author":"Park","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2011.35.6345","article-title":"ROS1 rearrangements define a unique molecular class of lung cancers","volume":"30","author":"Bergethon","year":"2012","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1093\/annonc\/mdt220","article-title":"The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma","volume":"24","author":"Kim","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.21037\/tcr-20-1813","article-title":"Clinical characteristics of patients with ROS1 gene rearrangement in non-small cell lung cancer: A meta-analysis","volume":"9","author":"Bi","year":"2020","journal-title":"Transl. Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_7","unstructured":"European Medicines Agency (2024). Xalkori: EPAR\u2014Product Information."},{"key":"ref_8","unstructured":"European Medicines Agency (2024). Rozlytrek: EPAR\u2014Product Information."},{"key":"ref_9","unstructured":"U.S. Food and Drug Administration (2024). USPI: Augtyro (Repotrectinib), Highlights of Prescribing Information."},{"key":"ref_10","unstructured":"U.S. Food and Drug Administration (2019). USPI: Rozlytrek (Entrectinib), Highlights of Prescribing Information."},{"key":"ref_11","unstructured":"U.S. Food and Drug Administration (2022). USPI: Xalkori (Crizotinib), Highlights of Prescribing Information."},{"key":"ref_12","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Non-Small Cell Lung Cancer V.11.2024. \u00a9 National Comprehensive Cancer Network. Inc. 2024. All rights reserved. Accessed [December 16 2024]. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/annonc\/mdz131","article-title":"Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): Updated results, including overall survival, from PROFILE 1001","volume":"30","author":"Shaw","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_14","first-page":"100332","article-title":"Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC","volume":"3","author":"Drilon","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/OP.20.00819","article-title":"The Road Less Traveled: A Guide to Metastatic ROS1-Rearranged Non\u2013Small-Cell Lung Cancer","volume":"17","author":"Almquist","year":"2021","journal-title":"JCO Oncol. Pract."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"D\u2019Angelo, A., Sobhani, N., Chapman, R., Bagby, S., Bortoletti, C., Traversini, M., Ferrari, K., Voltolini, L., Darlow, J., and Roviello, G. (2020). Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies. Cancers, 12.","DOI":"10.3390\/cancers12113293"},{"key":"ref_17","first-page":"1717","article-title":"The incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib","volume":"13","author":"Patil","year":"2018","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Fan, Y., Drilon, A., Chiu, C.H., Bowles, D.W., Loong, H.H.F., Siena, S., Goto, K., Krzakowski, M., Ahn, M.J., and Murakami, H. (2022, January 6\u20139). Entrectinib in Patients with ROS1 Fusion Positive NSCLC: Updated Efficacy and Safety Analysis. Proceedings of the 2022 World Conference on Lung Cancer, Vienna, Austria.","DOI":"10.1016\/j.jtho.2022.07.150"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa2302299","article-title":"Repotrectinib in ROS1 Fusion\u2013Positive Non\u2013Small-Cell Lung Cancer","volume":"390","author":"Drilon","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_20","unstructured":"U.S. Food and Drug Administration (2023). FDA Approves Repotrectinib for ROS1-Positive Non-Small Cell Lung Cancer."},{"key":"ref_21","unstructured":"European Medicines Agency (2024, November 11). Augtyro. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/augtyro."},{"key":"ref_22","unstructured":"European Network for Health Technology Assessment (2022). Direct and Indirect Comparisons, EUnetHTA Secretariat."},{"key":"ref_23","unstructured":"Phillippo, D., Ades, T., Dias, S., Palmer, S., Abrams, K.R., and Welton, N. (2016). NICE DSU Technical Support Document 18: Methods for Population-Adjusted Indirect Comparisons in Submissions to NICE, NICE Decision Support Unit."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","article-title":"Matching-Adjusted Indirect Comparisons: A New Tool for Timely Comparative Effectiveness Research","volume":"15","author":"Signorovitch","year":"2012","journal-title":"Value Health"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1200\/JCO.2017.75.5587","article-title":"Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer","volume":"36","author":"Wu","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1002\/cam4.2972","article-title":"First-line crizotinib versus platinum-pemetrexed chemotherapy in patients with advanced ROS1-rearranged non-small-cell lung cancer","volume":"9","author":"Shen","year":"2020","journal-title":"Cancer Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.jtho.2018.04.016","article-title":"Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer","volume":"13","author":"Li","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.lungcan.2020.07.016","article-title":"Effectiveness and prognostic factors of first-line crizotinib treatment in patients with ROS1-rearranged non-small cell lung cancer: A multicenter retrospective study","volume":"147","author":"Zheng","year":"2020","journal-title":"Lung Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11523-021-00860-z","article-title":"Real-World Outcomes Among Crizotinib-Treated Patients with ROS1-Positive Advanced Non-Small-Cell Lung Cancer: A Community Oncology-Based Observational Study","volume":"17","author":"Waterhouse","year":"2022","journal-title":"Target. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1111\/1759-7714.13681","article-title":"Prognostic factors for survival in patients with metastatic lung adenocarcinoma: An analysis of the SEER database","volume":"11","author":"Crama","year":"2020","journal-title":"Thorac. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/bjc.2017.232","article-title":"Lung cancer prognostic index: A risk score to predict overall survival after the diagnosis of non-small-cell lung cancer","volume":"117","author":"Alexander","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e000344","DOI":"10.1136\/esmoopen-2018-000344","article-title":"Gender and outcomes in non-small cell lung cancer: An old prognostic variable comes back for targeted therapy and immunotherapy?","volume":"3","author":"Pinto","year":"2018","journal-title":"ESMO Open"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.jtho.2019.03.020","article-title":"Safety and Efficacy of Crizotinib in Patients with Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial","volume":"14","author":"Michels","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"107253","DOI":"10.1016\/j.lungcan.2023.107253","article-title":"Real-world treatment patterns and survival of patients with ROS1 rearranged stage IV non-squamous NSCLC in the Netherlands","volume":"181","author":"Damhuis","year":"2023","journal-title":"Lung Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1002\/cam4.4789","article-title":"Association of anticoagulant use with clinical outcomes from crizotinib in ALK- and ROS1-rearranged advanced non-small cell lung cancers: A retrospective analysis of PROFILE 1001","volume":"11","author":"Ng","year":"2022","journal-title":"Cancer Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/0272989X17725740","article-title":"Methods for Population-Adjusted Indirect Comparisons in Health Technology Appraisal","volume":"38","author":"Phillippo","year":"2018","journal-title":"Med. Decis. Mak."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Guyot, P., Ades, A.E., Ouwens, M.J.N.M., and Welton, N.J. (2012). Enhanced secondary analysis of survival data: Reconstructing the data from published Kaplan-Meier survival curves. BMC Med. Res. Methodol., 12.","DOI":"10.1186\/1471-2288-12-9"},{"key":"ref_38","first-page":"100406","article-title":"Final Overall Survival, Safety, and Quality of Life Results From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced NSCLC","volume":"3","author":"Wu","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1093\/annonc\/mdz407","article-title":"Crizotinib in c-MET- or ROS1-positive NSCLC: Results of the AcSe phase II trial","volume":"30","author":"Cozic","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"S421","DOI":"10.1016\/j.jtho.2022.07.730","article-title":"Crizotinib in ROS1+ NSCLC: Long-term OS Analysis in Patients with Brain Metastases Included in the Phase II METROS Trial","volume":"17","author":"Cappuzzo","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"7312","DOI":"10.1158\/1078-0432.CCR-19-0994","article-title":"Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial","volume":"25","author":"Landi","year":"2019","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"9078","DOI":"10.1200\/JCO.2022.40.16_suppl.9078","article-title":"Crizotinib in ROS1-rearranged lung cancer (EUCROSS)\u2014Updated overall survival","volume":"40","author":"Michels","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41571-020-0408-9","article-title":"ROS1-dependent cancers\u2014Biology, diagnostics and therapeutics","volume":"18","author":"Drilon","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1002\/1878-0261.13214","article-title":"Pre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumours treated with entrectinib","volume":"16","author":"Dziadziuszko","year":"2022","journal-title":"Mol. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jtho.2023.12.008","article-title":"Comprehensive Review of ROS1 Tyrosine Kinase Inhibitors-Classified by Structural Designs and Mutation Spectrum (Solvent Front Mutation [G2032R] and Central \u03b2-Sheet 6 [C\u03b26] Mutation [L2086F])","volume":"19","author":"Ou","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00063","article-title":"Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer","volume":"2017","author":"Gainor","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2217\/cer-2020-0063","article-title":"Matching-adjusted indirect comparison: Entrectinib versus crizotinib in ROS1 fusion-positive non-small cell lung cancer","volume":"9","author":"Chu","year":"2020","journal-title":"J. Comp. Eff. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.2217\/fon-2021-1102","article-title":"Effectiveness of crizotinib versus entrectinib in ROS1-positive non-small-cell lung cancer using clinical and real-world data","volume":"18","author":"Tremblay","year":"2022","journal-title":"Future Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"107816","DOI":"10.1016\/j.lungcan.2024.107816","article-title":"Efficacy and safety of crizotinib in the treatment of advanced non-small cell lung cancer with ROS1 gene fusion: A systematic literature review and meta-analysis of real-world evidence","volume":"192","author":"Nadal","year":"2024","journal-title":"Lung Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1007\/s12325-023-02520-2","article-title":"A Critical Appraisal of Matching-Adjusted Indirect Comparisons in Spinal Muscular Atrophy","volume":"40","author":"Jiang","year":"2023","journal-title":"Adv. Ther."},{"key":"ref_51","unstructured":"EUnetHTA (2022). Methods Guideline: D4.3.2 Indirect Comparisons, EUnetHTA Secretariat. 1.0."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"TPS9141","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS9141","article-title":"A randomized phase 3 study of entrectinib versus crizotinib in patients (pts) with locally advanced\/metastatic ROS1 fusion-positive (fp) NSCLC with or without baseline CNS metastases (mets)","volume":"40","author":"Dingemans","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_53","unstructured":"ClinicalTrials.gov (2024). A Study of Repotrectinib Versus Crizotinib in Participants with Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-Na\u00efve ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1002\/sim.8759","article-title":"Assessing the performance of population adjustment methods for anchored indirect comparisons: A simulation study","volume":"39","author":"Phillippo","year":"2020","journal-title":"Stat. Med."},{"key":"ref_55","unstructured":"Phillippo, D.M., Dias, S., Ades, A.E., and Welton, N.J. (2024). Multilevel Network Meta-Regression for General Likelihoods: Synthesis of Individual and Aggregate Data with Applications to Survival Analysis, Cornell University."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/5\/748\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:40:25Z","timestamp":1760028025000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/5\/748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,22]]},"references-count":55,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["cancers17050748"],"URL":"https:\/\/doi.org\/10.3390\/cancers17050748","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,22]]}}}